AGO1

Across TCGA pan-cancer cohorts, AGO1 Mutation is linked to patient survival in 9 of 34 cancer types, making it a survival-associated AGO1 data layer compared with 23 for mass-spec protein and 5 for mass-spec protein.

The strongest signal is observed in breast invasive carcinoma (BRCA), where higher AGO1 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated AGO1 expression acts as an unfavorable survival marker, although some lineages such as LUAD show a favorable association.

BRCA, THYM, and KIRC are the cancer types where AGO1 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
BRCA	OS	Median	III,IV	0.140	0.833	<.001	24	view →
THYM	OS	Median	All	0.186	0.931	<.001	15	view →
KIRC	OS	Median	All	0.249	0.805	.010	12	view →
STAD	OS	Median	II,III,IV	0.500	0.660	.004	10	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →
LIHC	DFS	Median	All	0.044	0.553	<.001	6	view →
UCEC	OS	Median	IV	0.346	0.764	<.001	6	view →
SCLC	OS	Median	All	0.219	0.650	.031	3	view →
LUAD	DFS	Median	All	1.000	0.328	.044	2	view →

Pink = unfavorable, green = favorable. Showing the 9 strongest of 9 lineages.

AGO1–BRCA (OS)

Open the BRCA breakdown →